1-(2-氟苯基)-3,3-二甲基-1-丁酮 | 898764-70-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2-氟苯基)-3,3-二甲基-1-丁酮
• 英文名称: 3,3-Dimethyl-2'-fluorobutyrophenone
• 英文别名: 1-(2-fluorophenyl)-3,3-dimethylbutan-1-one
• CAS: 898764-70-0
• 化学式: C₁₂H₁₅FO
• 分子量: 194.249
• InChiKey: GSAGLACKEKPELM-UHFFFAOYSA-N

物化性质

• 沸点：
  249.4±13.0 °C(Predicted)
• 密度：
  1.015±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  1-(2-氟苯基)-3,3-二甲基-1-丁酮 在 lithium aluminium tetrahydride 、 三溴化磷 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醚 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 38.5h， 生成
  参考文献：
  名称：

  The design and synthesis of novel, phosphonate-containing transient receptor potential melastatin 8 (TRPM8) antagonists

  摘要：

  A series of benzothiophene-based phosphonates was synthesized and many analogs within the series were shown to be potent antagonists of the TRPM8 channel. The compounds were obtained as a racemic mixture in 5 synthetic steps, and were tested for TRPM8 antagonist activity in a recombinant, canine TRPM8-expressing cell line using a fluorometric imaging plate reader (FLIPR) assay. Structure-activity relationships were developed initially by modification of the core structure and subsequently by variation of the aromatic substituents and the phosphonate ester. Compound 9l was administered intraperitoneally to rats and demonstrated engagement of the TRPM8 target in both prevention and reversalmodes in an icilin-induced 'wet-dog' shake model. (C) 2012 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2012.02.060

文献信息

• COLD MENTHOL RECEPTOR-1 ANTAGONISTS
  申请人：Colburn Raymond W.

  公开号：US20120053347A1

  公开（公告）日：2012-03-01

  The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or conditions using compounds of the invention are also described.

  这项发明涉及式(I)的TRPM8拮抗剂。更具体地，本发明涉及某些新颖化合物，制备化合物的方法，组合物，中间体及其衍生物，以及治疗TRPM8介导的疾病的方法。还描述了使用本发明化合物治疗疼痛和各种其他疾病状态或病情的药用和兽医组合物及治疗方法。
• PANICINOTAM DERIVATIVE, PREPARATION METHOD AND USE THEREOF
  申请人：OCEAN UNIVERSITY OF CHINA

  公开号：US20210008045A1

  公开（公告）日：2021-01-14

  Provided are penicinotam derivatives, a tautomer, a stereoisomer, a racemate, a nonequal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and a pharmaceutical composition comprising the derivatives. Also provided herein is use of the derivatives and the pharmaceutical compositions in treating diseases caused by inflammation, immune system disorders.

  提供了青霉素衍生物、一个互变异构体、一个立体异构体、一个消旋体、一个非对映异构体的不等混合物、一个几何异构体、一个溶剂合物、一个药学上可接受的盐或其前药，以及包含这些衍生物的药物组合物。本文还提供了这些衍生物和药物组合物在治疗由炎症、免疫系统紊乱引起的疾病中的用途。
• Lactam Compound, Preparation Method and Use thereof
  申请人：OCEAN UNIVERSITY OF CHINA

  公开号：US20200030312A1

  公开（公告）日：2020-01-30

  Provided is a lactam compound, a tautomer, a stereoisomer, a racemate, a nonequal mixture of enantiomers, a geometric isomer, a solvate, a pharmaceutically acceptable salt thereof, or a solvate of the salt of the compound, and a pharmaceutical composition containing the compound. Also provided are the use of such compounds and their pharmaceutical compositions as drugs, especially as antiviral drugs.

  提供一种内酰胺化合物，一个互变异构体，一个立体异构体，一个拉克酸盐，一个非对映异构体的不等混合物，一个几何异构体，一个溶剂合物，其药学上可接受的盐，或者该化合物的盐的溶剂合物，以及含有该化合物的药物组合物。还提供了这些化合物及其药物组合物作为药物的用途，尤其是作为抗病毒药物。
• NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Boléa Christelle

  公开号：US20100137336A1

  公开（公告）日：2010-06-03

  The present invention relates to novel compounds of Formula (I), wherein X 1 , X 2 , X 3 , X 4 , A m and B n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

  本发明涉及公式（I）的新化合物，其中X1、X2、X3、X4、A和Bn的定义如公式（I）中所述；发明化合物是代谢型谷氨酸受体-亚型4（“mGluR4”）的调节剂，可用于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病。本发明还涉及制药组合物及其在制造药物方面的使用，以及在涉及mGluR4的疾病的预防和治疗中使用此类化合物。
• Novel amido derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
  申请人：Bolea Christelle

  公开号：US20110257182A1

  公开（公告）日：2011-10-20

  The present invention relates to novel compounds of Formula (I), wherein X 1 , X 2 , X 3 , X 4 , A m and B n are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR4 is involved.

  本发明涉及一种新型的化合物，其化学式为(I)，其中X1、X2、X3、X4、A和Bn的定义如化学式(I)中所示；发明的化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，可用于治疗或预防中枢神经系统疾病以及其他由mGluR4受体调节的疾病。本发明还涉及制药组合物以及使用这些化合物制备药物的方法，以及使用这些化合物预防和治疗涉及mGluR4的疾病的方法。